The dismissal of 0.05-0.125 mg sema usually goes: STEP trials used 0.25 mg as the floor because that’s the minimum showing meaningful receptor activation in phase 2 dose-finding, so anything below is sub-therapeutic noise. That argument is correct for weight loss. It’s not necessarily the answer to what the microdose community is actually asking. The phase 3 trials were powered to detect bodyweight change. That’s the primary endpoint, and the dose-response curve for appetite suppression is steep through the 0.25-2.4 mg range – which is why the titration schedule exists. But GLP-1 receptor signaling isn’t a single pathway. The appetite/metabolic axis runs through different downstream signaling than the neuroinflammatory and neuroprotective effects that people are actually citing when they report brain fog improvement at low doses. Whether those two pathways have the same dose-response threshold is, as far as I can tell, genuinely unanswered in humans. The rodent neuroinflammation literature uses doses that don’t translate cleanly. The STEP trials weren’t designed to detect it. So the honest position is: the weight loss dose-response data doesn’t close this question, it just doesn’t open it. Two confounds worth naming before accepting the anecdotes either way: First, the self-selection problem. People reporting effects at 0.05 mg are almost exclusively prior therapeutic-dose users maintaining post-loss. Their baseline receptor sensitivity, endogenous GLP-1 tone, and body composition aren’t representative of a naive population. Second, the half-life profile at microdose is qualitatively different – the weekly peak-to-trough curve at 0.05 mg produces plasma concentrations that barely register compared to therapeutic dosing. Whether intermittent sub-threshold pulses do anything mechanistically is a different question than steady-state receptor occupancy. “Experimental” is the right label. But the specific mechanism that would need studying to answer this isn’t the one the weight loss trials measured.
the thing nobody’s flagged is whether 0.05mg is even reliably 0.05mg. at that volume off a compounded vial you’re drawing maybe 2-3 units, and the measurement error on an insulin syringe at that mark is not trivial, plus whatever variance is already baked into the compounder’s concentration. so the “dose” in these self-reports has a confidence interval people aren’t accounting for, which muddies the dose-response question before you even get to the pathway split. separate thing, but the appetite axis and the brain fog reports might not be cleanly independent either. better glucose stability alone can clear a fair amount of fog, and that doesn’t need the neuroprotective pathway to be doing anything. concurrent isn’t causal. fwiw, not proof either way, just two more confounders before anyone reads signal into the anecdotes.
the syringe precision point lands harder than it usually gets credit for - 2-3 units at that mark is a real accuracy floor, not just noise, and whatever concentration variance is already baked into the compounded vial stacks on top. so the “dose” in these self-reports is a range, not a number. where I’d push back slightly on the glucose-fog conflation: if you can’t confirm the dose is even consistent session to session, you also can’t confirm glucose is moving consistently enough to attribute anything to it. the confounds don’t resolve each other, they compound.
“the confounds don’t resolve each other, they compound” is the right frame, and I’d hold onto it, because it’s the part most of these threads skip past. Where I’d add a wrinkle though: even if you could pin the dose to an exact 0.05mg session to session, you still wouldn’t have a clean line to glucose, because plasma AUC and receptor-level response don’t track each other linearly at these volumes. A consistent dose doesn’t buy you a consistent receptor signal, especially at intermittent sub-threshold pulses where occupancy is doing something quite different from steady state. So the glucose attribution has two broken links in the chain, not one, and confirming the dose only fixes the first. The other thing I’d gently flag is that the low-dose fog reports might not live on the glucose pathway at all, in which case chasing dose-to-glucose consistency is tightening a correlation that was never the mechanism. fwiw I tried logging my own dose, a rough fog score, and morning glucose for a stretch, and the correlation view did surface a loose dose-vs-fog pattern, but I genuinely couldn’t separate that from sleep, which with a toddler is its own confound that never resolves either. None of that is proof of nothing happening at microdose, just that the dose isn’t the unit I’d build the case on. ymmv. and worth raising any of this with the prescriber, not a forum.
The self-selection point is even worse than unrepresentative baseline. The same people reporting fog improvement at 0.05mg already dropped significant weight, and the fog lifts on its own once inflammation comes down and sleep consolidates post-loss, so they’re crediting the microdose for a clearing that the earlier loss probably did most of the work on. Untangling that would need a naive arm holding weight stable, which is exactly the population nobody’s microdosing.
The self-selection confound is the one I’d weight most heavily here. People maintaining post-loss at 0.05 mg aren’t just a different population, they’re running a qualitatively different experiment, and stacking their anecdotes with naive-user data as if it’s one dataset muddies both questions rather than answering either.